The UK and US have agreed to a important trade agreement that will keep no duties on UK pharmaceutical products being sold in the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the NHS. This move ensures that duties on these crucial products will be held at zero for a period of the next three years.
This development comes after previous threats to dramatically increase tariffs on branded pharmaceutical products, with figures floated reaching 100%.
"This deal with the Britain reinforces the global environment for new treatments and establishes much-needed equity to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Impact
Medicines are one of the UK's largest goods shipped to the United States, which is by far the primary market for major companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months prior to last September, the UK shipped pharmaceutical products worth billions to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee secures employment, boosts investment and facilitates the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Key NHS Changes
The deal includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to increase total public funding on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at fifteen percent. In the past, refunds exceeded 20%.
Recent Tensions
The pact comes amid a long-running tension between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by assertions that American customers were paying a premium for the identical medicines than people in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial investments have been announced toward US facilities.
A senior figure acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had decreased as a percentage of its overall budget over the last ten years.
